Marshall Wace, LLP Y M Abs Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 15,509 shares of YMAB stock, worth $172,770. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,509Holding current value
$172,770% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding YMAB
# of Institutions
106Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$45.5 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$32.7 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$24.4 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$22.7 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$20.4 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $487M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...